High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis
The prognostic significance of Ki-67 expression in patients with ovarian cancer was controversial in various studies. Therefore, we carried out a meta-analysis to determine the prognostic significance of Ki-67 in ovarian cancer patients.
We searched PubMed, Cochrane Library, EMBASE, Web of Knowledge, China National Knowledge Infrastructure database and WanFang digital database for eligible studies from January 1, 1990 to June 1, 2017. The pooled hazard ratios and 95% confidence intervals were calculated to assess the prognostic significance of Ki-67 expression for overall survival in ovarian cancer patients.
Finally, 38 eligible studies and 5004 ovarian cancer patients were included in the current study. The pooled hazard ratio was 1.35 (95% confidence interval 1.24–1.46, P = 0.001) for overall survival in ovarian cancer patients. The funnel plot bias was obviously asymmetrical and Egger’s test also detected significant publication bias (P = 0.001). The Contour-enhanced funnel plot with trim-and-fill method supplemented 11 dummy studies to balance the funnel plot and nine new supplementary studies were in area with statistical significance. Sensitivity analysis and cumulative meta-analysis further demonstrated that the association between high Ki-67 expression and poor overall survival of ovarian cancer patients was stable and reliable.
High Ki-67 expression is significantly related to poor overall survival and may serve as a prognostic biomarker for ovarian cancer patients.
KeywordsOvarian cancer ki-67 Meta-analysis Prognostic value
Conceptualization: ZZ, DQ, WC. Data curation: ZZ, WC. Formal analysis: ZZ, WC. Funding acquisition: ZZ. Investigation: ZZ, WC, DQ. Methodology: ZZ, WC, DQ. Project administration: ZZ, DZ. Resources: ZZ, HL. Software: ZZ, DZ, HL. Supervision: ZZ, WC. Validation: ZZ, DQ,WC. Visualization: ZZ, HL. Writing - original draft: ZZ, WC. Writing- review& editing: ZZ, WC.
This study was funded in part by Health Department and Finance Department of Guangdong Province. The Grant Numbers were No: B2018237 (Grant Recipient: Zhiqiao Zhang) and No: A2016450 (Grant Recipient: Zhiqiao Zhang).The total funding account was RMB 5000. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The URLs of Health Department of Guangdong Province was https://www.gdwst.gov.cn/.
Compliance with ethical standards
Conflict of interest
The authors have declared that they had no conflict of interests in relation to the work described. The authors have declared that they have had full control of all primary data and that they agreed to allow the Journal to review their data if requested.
The present study is a meta-analysis and ethical approval is not needed for meta-analysis.
- 3.Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD et al (1993) The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123:513–522CrossRefGoogle Scholar
- 12.Lee JS, Choi YD, Choi C, Lee MC, Park CS, Min KW (2005) Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth. Anal Quant Cytol Histol 27:202–210Google Scholar
- 18.Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G, Morris DL (2015) Sprouty 1 predicts prognosis in human epithelial ovarian cancer. Am J Cancer Res 5:1531–1541Google Scholar
- 19.Khandakar B, Mathur SR, Kumar L, Kumar S, Datta Gupta S, Iyer VK et al (2014) Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int 401245Google Scholar
- 24.Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH (2011) The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4:444–453Google Scholar
- 25.Kondoh E, Mori S, Yamaguchi K, Baba T, Matsumura NC, Barnett J et al (2010) Targeting slow-proliferating ovarian cancer cells. Int J Cancer 126:2448–2456Google Scholar
- 32.Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, Furuya K et al (2007) Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol 31:999–1006CrossRefGoogle Scholar
- 34.Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H et al (2006) Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol 21:713–720Google Scholar
- 36.Elie C, Geay JF, Morcos M, Tourneau A, Girre V, Broet P et al (2004) Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 91:470–475CrossRefGoogle Scholar
- 38.Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281–287Google Scholar